Headlines about Bristol-Myers Squibb (NYSE:BMY) have trended somewhat positive this week, according to Accern. The research group identifies negative and positive media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Bristol-Myers Squibb earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.7354155232371 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news articles that may have impacted Accern’s scoring:
- Should Bristol-Myers panic over Incyte’s skin cancer failure? (statnews.com)
- How a Biotech Bummer Sent Nektar Therapeutics Stock South Today (finance.yahoo.com)
- Bristol-Myers Squibb (BMY) Given New $72.00 Price Target at Citigroup (americanbankingnews.com)
- Bristol-Myers Squibb Company Reminder: Important April 10, 2018 Lead Plaintiff Deadline in Class Action– BMY (finance.yahoo.com)
- Cancer killer: Tampa’s ‘best-kept secret’ M2Gen collects data from labs and bedsides to help target treatments (finance.yahoo.com)
Several equities analysts have recently commented on BMY shares. Argus reaffirmed a “buy” rating and issued a $66.43 target price (down previously from $75.00) on shares of Bristol-Myers Squibb in a research report on Wednesday, March 21st. Vetr downgraded Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $60.72 price target on the stock. in a research report on Tuesday, January 16th. Zacks Investment Research raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Friday, January 19th. JPMorgan Chase set a $75.00 price target on Bristol-Myers Squibb and gave the stock an “overweight” rating in a research report on Tuesday, March 20th. Finally, Credit Suisse Group set a $62.00 price target on Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Monday, January 22nd. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $66.68.
Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.01. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The firm had revenue of $5.45 billion during the quarter, compared to analysts’ expectations of $5.35 billion. During the same period in the prior year, the company earned $0.63 earnings per share. The company’s quarterly revenue was up 3.9% on a year-over-year basis. sell-side analysts expect that Bristol-Myers Squibb will post 3.22 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, May 1st. Shareholders of record on Friday, April 6th will be paid a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 2.63%. The ex-dividend date of this dividend is Thursday, April 5th. Bristol-Myers Squibb’s payout ratio is presently 53.16%.
ILLEGAL ACTIVITY NOTICE: This story was reported by Ticker Report and is the property of of Ticker Report. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.tickerreport.com/banking-finance/3336272/bristol-myers-squibb-bmy-receiving-somewhat-positive-press-coverage-study-finds.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.